Egetis Therapeutics AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EGTX.ST research report →
Companywww.egetis.com
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
- CEO
- Nicklas Westerholm
- IPO
- 2011
- Employees
- 38
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $2.52B
- P/E
- -7.04
- P/S
- 39.88
- P/B
- 10.60
- EV/EBITDA
- -6.86
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 14.24%
- Op Margin
- -587.34%
- Net Margin
- -592.09%
- ROE
- -122.72%
- ROIC
- -111.47%
Growth & Income
- Revenue
- $62.40M · 35.36%
- Net Income
- $-342,500,000 · 0.32%
- EPS
- $-0.93 · 16.96%
- Op Income
- $-346,900,000
- FCF YoY
- -17.86%
Performance & Tape
- 52W High
- $7.07
- 52W Low
- $3.02
- 50D MA
- $5.85
- 200D MA
- $5.39
- Beta
- 0.76
- Avg Volume
- 925.73K
Get TickerSpark's AI analysis on EGTX.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EGTX.ST Coverage
We haven't published any research on EGTX.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EGTX.ST Report →